Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS2943022 A
Publication typeGrant
Publication dateJun 28, 1960
Filing dateFeb 25, 1958
Priority dateFeb 25, 1958
Publication numberUS 2943022 A, US 2943022A, US-A-2943022, US2943022 A, US2943022A
InventorsDoppstadt Adolph, Siemer Harm
Original AssigneeRavensberg G M B H
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Substituted 1-phenyl-2, 3-dimethyl-4-morpholino methyl pyrazolone-(5) compounds and process of making same
US 2943022 A
Previous page
Next page
Description  (OCR text may contain errors)

' Patented: June 28, 1960;

I 2,943,022 SUBSTITUTED l-PHENYL-ZJ-DHVIE'IHYLA-MOR- PHOLINO METHYL PYRAZOLONE-(S) COM- POUNDS AND' PROCESS OF MAKING SAME Harm Siemer, Konstanz, and Adolph Doppstadt, Konstanz-Litzelstetten, Germany, assignors to Ravensberg G.m.b.H., Chemische Fabrik, Konstanz, Germany, a corporation of Germany No Drawing. Filed Feb. 25, 1958, Ser. No. 717,332 10 Claims. (Cl.1'67.--65) The present invention relates to valuable analgesic agents and more particularly to substituted l-phenyl- 2,3-dimethyl-4-morpholino methyl pyrazolone-(5) compounds and to a process of making same.

It is one object ofthe present invention to provide new and valuable analgesic agents which are far superior in their analgesic activity than any of the commonly used analgesic agentssuch as 1-phenyl-2,3-dimethyl-4- dimethylamino pyrazolone-(5), salicylic acid amide, aceto phenetidinc, and others.

Another object of the present invention is to provide a new and simpleprocess of producing such valuable analgesic 1-phenyl-2,3-diinethyl-4-morpholino methyl pyrazolone-(S) compounds. A further object of the present invention is to provide valuable analgesic preparations such as tablets or injectable solutions-containing, as active analgesic ingredient, said 1 phenyl 2,3-dimethyl-4-morpholinomethyl pyrazclone-(5). compounds. I p 1 Other objects of the. present invention and advantageous features thereof will become apparent as the description proceeds. I

The new analgesic substituted l-pheny1-2,3-dimethyl- 4-morpho1ino methyl pyrazolone- (5) compounds accord: ing to the present invention are compounds of the following formula In said formula R indicates a lower alkyl group with l to 5 carbon atoms arranged in a straight or branched chain.

Such new and valuable analgesic 1-phenyl-2,3-dimethyl- 4-morpholino methyl pyrazolone compounds are produced in a surprisingly simple manner and in a good yield by adding to an alcoholic solution of the corresponding substituted morpholine compounds, for instance, to 2-phenyl'-3.-methyl morpholine, formaldehyde and an aqueous hydrochloric acid solution of l-phenyl-2,3-dimethyl pyrazolone-(5) and stirring the mixture on the water bath at a temperature of 25-30 C., for several hours, preferably for 2 hours.

When proceeding in this manner, the hydrochlorides of the reaction products, such as the hydrochloride of 1-phenyl-2,3.-dimethyl-4-(2'-phenyl-3-methyl morpholino methyl) pyrazolone-(5) precipitate from the reaction solution and can be recrystallized from a mixture of alcohol and acetone, if required. Addition of alkali hydroxide solution to the aqueous solution of the hydrochlorides yields the corresponding bases which are obtained in solid form;

. The new compounds have a high analgesic activity. The following table shows the results obtained on pharmacologically testing the new'compound in comparison with Well-known analgesic agents. The dose given is the mean therapeutic dose (AD H) determined according to the method of Wolff-Hardy by focusing rays of a strong light source on the blackened forehead of a test individual.

TABLE Compound tested ADg II A f 1-Pheny1-2,3- methyl-4-dimethyl amino pyrazolone-(5).. 120 Salicylic acid amide 540 Aceto plienetidine 500 i-Phenyl-2,3-dimethyl-4- (2-phenyl-3-rnethyl morphoiino methyl) pyrozolone-(5).HC1 55 It is evident that the new compound has an analgesic activity which is twice as strong as that of the known pyrazolone derivative and about ten times as strong as that of salicylic acid amide or aceto phenetidine. When taking into consideration that the analgesic activity of 1-phenyl-2,3-dimethyl pyrazolone amounts to only one third of the activity of the tested compound l-phenyl- 2,3-dimethyl-4-dimethylamino pyrazalone, it follows that r position. Therefore, they represent new and valuable pharmaceutical compounds, especially in the form of their pharmaceutically acceptable acid addition salts. Solutions of the salts, especially solutions of salts with organic acids, are suitable for injection because they are well tolerated by the human body.

The analgesic compounds according to the present invention can be used in the form of their readily soluble salts with gentisic acid or ascorbic acid for preparing highly concentrated injectable solutions thereof. Such solutions are prepared, for instance, by dissolving the insoluble base, suspended in finely divided form in water, by the addition of the corresponding organic acid, whereby the pH-value is adjusted to a neutral or, respec-. tively, weakly acid pH-yalue between about 6.0 and about 7.0. The gentisic acid salt of the new pyrazolone compoundcan also be prepared, for instance, byreacting equimolecular amounts of gentisic acid and the base in a mixture of: methanol and acetone while heating. The resulting salt crystallizes on cooling. It is separated from the. methanolracetone mixture and is then dissolved in Example 1 35.4 g. of 2-phenyl-3-methyl morpholine are dissolved in '50 cc. of methanol. 20 cc. of an aqueous 40% formaldehyde solution are added thereto while cooling. A solution. of 37.6 g. of 1-phenyl-2,3-dimethyl pyrazolone (5) in a mixture of 35 cc. of water and 20 cc. of concentrated hydrochloric acidare added at once to said reaction mixture. The pH-value of the resulting mixture is adjusted to apH'between about 2.0 and about 3.0 and the acid reaction mixture is then stirred on the water bath-at a. temperature of 25-30 C. for two hours. The precipitated hydrochloride is, recrystallized'fi'om a mixture of methanol and acetone (1:1).

. The melting point of the recrystallized hydrochloride. of 1-pheny1-2,3 -dimethyl 4 (2-phenyl 3'-methy1 morpholino methyl) pyrazolone-(S) is 171-172" C. (with decomposition). Yield: 81.6%. The corresponding base is obtained by rendering alkaline the solution of said hydrochloride by the addition of sodium hydroxide solution, extraction by means of chloroform and evaporation of the extracting solvent. It has a melting point of 149-150 C.

Example 2 38.2 g. of 2-phenyl-3-ethyl morpholine are reacted with 37.6 g. of l-phenyl-2,3-dimethyl pyrazolone-(S) by following the procedure described hereinabove in Example 1. The yield of l-phenyl-2,3-dimethyl-4(2' phenyl-3'ethyl morpholino methyl) pyrazolone-(S) hydrochlon'de is 82.2%. The melting point of the hydrochloride is 174-175 C. (with decomposition) after recrystallization from a mixture of acetone and methanol (1:1).

Example 3 I The free base of l-phenyl-2,3-dimethyl-4-(2-phenyl-3'- methyl morpholino methyl) pyrazolone-(S) obtained according to Example 1 is dissolved in methanol. An equimolecular amount of gentisic acid is added thereto and the mixture is heated under reflux for one hour. After cooling, an amount of acetone corresponding to the amount of methanol is added, whereupon the addition salt with gentisic acid crystallizes. It melts at 169-l70 C. (with decomposition).

Example 4 1.575 g. of ascorbic acid and 0.425 g. of gluconic acid lactone are dissolved in 15 cc, of distilled water at a temperature of about 40 C. Thereto there are added 3.75 g. of l-phenyl-2,3 dimethyl 4 (2'-phenyl-3-n1ethyl-morpholino methyl)-pyrazolone-(5) and, subsequently, 3.5 g. of salicylamide-O-sodium acetate. The mixture is then filled up to a volume of 25 cc. with distilled water and the filtered solution is filled into ampoules of a capacity of 5 cc. hTrlire ampoules are sterilized according to customary met s.

Example 1-phenyl-2,3-dimethyl-4 (2-phenyl 3' methylmorpholinomethyl)-pyrazolone-(5)is reacted, in accordance with Example 3, with an equimolar amount of salicylamide-O-acetic acid. After cooling, the reaction solution is stirred with ether until it remains turbid and crystals precipitate on standing. The crystalline salt of the salicylamide-O-acetic acid melts at a temperature between 112 C. and 113 C. (with decomposition). This salt is suitable for making tablets.

In place of the 2-phenyl-3-methyl morpholine' compound used in the preceding examples, there may be employed equimolecular amounts of other 2-phenyl morpholine compounds substituted in 3-position by a lower alkyl radical having a straight or branched chain, such as 2-phenyl-3-n-propyl morpholine, 2-phenyl-3-isopropyl morpholine, and the like, while otherwise the procedure is the same as given in said examples.

In place of the hydrochloride and the gentisic acid salt described in the preceding examples, there may be prepared other acid addition salts such as salts with inorganic acids, for instance, with sulfuric acid, phosphoric acid, hydrobromic acid, nitric acid, or with other-organic acids, such as with tartaric acid, citric acid, malic acid, acetic acid, benzoic' acid, salicylic acid, nicotinic acid, and others. V

For therapeutical administration the new 1'-phenyl-2,3- dimethyl-4-(2'-phenyl-3-lower alkyl morpholino methyl) pyrazolone-(S) compounds or their acid'addition salts and preferably their salts with gentisic acid or ascorbic acid are incorporated into pharmaceutical excipients and are used, for instance, in the form of tablets, dragees, capsules, pills, suppositories, sirups, and the like preparations. Such. tablets and other preparations contain at least 15 of the active ingredient. Its percentage in the preparation may be varied and is preferably between about 15% and about 60% of the weight of the tablet or preparation. It is, of course, also possible to use greater amounts of the active ingredient although with such greater amounts administration of a suitable dosage becomes more diflicult. Preferred preparations according to the present invention are prepared in such a manner that a dosage unit form of tablet and the like preparation contains between about 50 mg. and about 250 mg. of an acid addition salt of 1-phenyl-2,3-dimethyl-.4-(2'- phenyl-3-lower alkyl morpholino methyl) pyrazolone- (5).

When preparing tablets, pills, dragees, and the like shaped solid preparations for oral administration, the commonly used diluting agents, binders, lubricants, and other tableting adjuvants are employed such as sugar, dextrose, lactose, starch, methyl cellulose, yeast extract, agar, tragacanth, and as lubricants stearic acid, magnesium stearate, and others.

Injectable solutions of the new analgesic compounds according to the present invention are prepared as described hereinabove in Example 3.

The eifective daily dose for an adult person is between about 100 mg. and about 800 mg. The preferred daily dose is about 400 mg. The dose is preferably given subdivided in 4 doses in intervals of 2 hours to 3 hours. Of course, larger or smaller doses may also be given if they are required.

With respect to the Wold-Hardy method for determining the therapeutic dose as mentioned in columne 2, lines 2-6, it may be mentioned that the prolongation of the reaction time in seconds subsequent to administration (30 to 45 minutes) was taken as the criterion concerning the analgesic activity of the substances tested. In this connection a prolongation of the reaction time by 8 seconds represents the analgesic stage H. In carrying out the tests, the preparations were injected in mice weighing from 20 g. to 25 g.

We claim:

1. l-phenyl-2,3-dimethyl-4-(2'-phenyl-3'-methyl morpholino methyl) pyrazolone-(S).

2. l-phenyl-2,3-dimethyl-4-(2 phenyl 3' ethyl morpholino methyl) pyrazolone-(S 3. The gentisic acid salt of l-phenyl-2,3-dimethyl-4-(2'- phenyl-3'-methyl morpholino methyl) pyrazolone-(S).

4. The hydrochloride of l-phenyl-2,3-dimethyl-4-(2- phenyl-3'-methyl morpholino methyl) pyrazolone-(S).

5. The hydrochloride of 1phenyl-2,3-dimethyl-4-(2- phenyl-3-ethyl morpholino methyl) pyrazolone-(S).

6. A substituted l-phenyl-2,3-dimethyl-4-morpholino methyl pyrazolone-(S) compound selected from the group consisting of 1-phenyl-2,3-dimethyl-4-(2'-phenyl-3-lower alkyl morpholino methyl) pyrazolone-(S) and its nontoxic pharmaceutically acceptable acid addition salts.

7. In the process of producing l-phenyl-2,3-dimethyl- 4-morpholino methyl pyrazolone-(S) compounds selected from the group consisting of 1-phenyl-2,3-dimethyl,-4-(2- phenyl-3'-lower alkyl morpholino methyl) pyrazolone- (5) and its non-toxic, pharmaceutically acceptable acid addition salts, the step which comprises gently heating an alcoholic solution of 2-phenyl-3-lower alkyl morpholine and formaldehyde with an aqueous acid solution of l-phenyl-2,3-dimethyl pyrazolone-(S) at a pH between about 2.0 and about 3.0 and separating the precipitated acid addition salt of the reaction product from the reaction mixture.

8. An analgesic composition comprising, as analgesic ingredient, not less than 15% of 1-phenyl-2,3-dimethyl-4- (2'-phenyl-3'-lower alkyl morpholino methyl) pyrazolone- (5) and a significant amount of a pharmaceutical carmen 9. An injectable analgesic composition comprising, as

analgesic ingredient, not less than 10% of the water soluy1-3-lower alkyl morpholino methyl) pyrazolone-(S) disfrom the group consisting of l-phenyl-2,3-dimethyl-4- solved in water. (2'-phenyl-3'-lower alkyl morpholino methyl) pyrazolone- 10. The process of alleviating pain comprising admin- (5) and its non-toxic, pharmaceutically acceptable acid istoring to persons suffering from pain a composition addition salt. comprising not less than 0.1% of a 1-phenyl-2,3-dimethyl- 6 4-morpholino methyl pyrazolone-(S) compound selected No references

Non-Patent Citations
1 *None
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3005818 *Apr 1, 1959Oct 24, 1961Ravensberg G M B H1-phenyl-2, 3-dimethyl-4-morpholino methyl pyrazolone-(5) compounds
US5512570 *May 25, 1995Apr 30, 1996Merck & Co., Inc.Treatment of emesis with morpholine tachykinin receptor antagonists
US5637699 *May 22, 1995Jun 10, 1997Merck & Co., Inc.Process for preparing morpholine tachykinin receptor antagonists
US5691336 *Sep 8, 1995Nov 25, 1997Merck & Co., Inc.Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
US5716942 *May 25, 1995Feb 10, 1998Merck & Co., Inc.Treatment of migraine with morpholine tachykinin receptor antagonists
US5719147 *Sep 8, 1995Feb 17, 1998Merck & Co., Inc.Morpholine and thiomorpholine tachykinin receptor antagonists
US5780467 *Aug 8, 1997Jul 14, 1998Merck & Co., Inc.Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
US5872116 *Oct 28, 1997Feb 16, 1999Merck & Co., Inc.Morpholine and thiomorpholine tachykinin receptor antagonists
US5922706 *Nov 13, 1997Jul 13, 1999Merck & Co., Inc.Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859 *Feb 16, 1999Apr 11, 2000Merck & Co., Inc.Morpholine and thiomorpholine tachykinin receptor antagonists
US6235735Mar 16, 2000May 22, 2001Merck & Co., Inc.Aftertreatment of radiation therapy
US6638930Apr 17, 2001Oct 28, 2003Merck & Co. Inc.Morpholine and thiomorpholine tachykinin receptor antagonists
U.S. Classification514/236.5, 544/140
International ClassificationC07D403/06
Cooperative ClassificationC07D403/06
European ClassificationC07D403/06